A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf
.
Plasma Galectin-3 and Heart Failure Outcomes in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy)
2014
Journal of Cardiac Failure
Elevated circulating levels of the protein galectin-3, a mediator of fibrogenesis, have previously been associated with adverse outcomes in heart failure (HF) patients and appear to modify response to certain pharmacologic therapies. This study investigated the relationship between galectin-3 level and clinical outcomes in HF patients randomized to implantable cardioverter defibrillator (ICDonly) or cardiac resynchronization therapy (CRT-D). Methods and Results: Plasma galectin-3 concentrations
doi:10.1016/j.cardfail.2014.07.018
pmid:25106783
fatcat:fiarogorhrbytb3i24gqdp32aa